156 related articles for article (PubMed ID: 37366384)
1. HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review.
Bencina G; Petrova E; Sönmez D; Matos Pereira S; Dimitriadis I; Salomonsson S
J Health Econ Outcomes Res; 2023; 10(1):102-110. PubMed ID: 37366384
[No Abstract] [Full Text] [Related]
2. Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer.
Wong SE; Everest L; Jiang DM; Saluja R; Chan KKW; Sridhar SS
JCO Oncol Pract; 2020 Feb; 16(2):e201-e210. PubMed ID: 32045549
[TBL] [Abstract][Full Text] [Related]
3. Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit.
Hofmarcher T; Szilagyiova P; Gustafsson A; Dolezal T; Rutkowski P; Baxter C; Karamousouli E
ESMO Open; 2023 Aug; 8(4):101593. PubMed ID: 37413761
[TBL] [Abstract][Full Text] [Related]
4. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
Kandolf Sekulovic L; Guo J; Agarwala S; Hauschild A; McArthur G; Cinat G; Wainstein A; Caglevic C; Lorigan P; Gogas H; Alvarez M; Duncombe R; Lebbe C; Peris K; Rutkowski P; Stratigos A; Forsea AM; De La Cruz Merino L; Kukushkina M; Dummer R; Hoeller C; Gorry C; Bastholt L; Herceg D; Neyns B; Vieira R; Arenberger P; Bylaite-Bucinskiene M; Babovic N; Banjin M; Putnik K; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Ymeri A; Stojkovski I; Garbe C
Eur J Cancer; 2018 Nov; 104():201-209. PubMed ID: 30388700
[TBL] [Abstract][Full Text] [Related]
5. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
[TBL] [Abstract][Full Text] [Related]
6. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
7. Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer.
Oudard S; Courbon F
Ann Oncol; 2017 Feb; 28(2):421-426. PubMed ID: 28426107
[TBL] [Abstract][Full Text] [Related]
8. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia.
Janzic U; Knez L; Janzic A; Cufer T
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):717-723. PubMed ID: 31826655
[No Abstract] [Full Text] [Related]
9. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS.
Yoon NR; Na YJ; Lee JH; Song I; Lee EK; Park MH
J Cancer Res Clin Oncol; 2024 Mar; 150(3):113. PubMed ID: 38436796
[TBL] [Abstract][Full Text] [Related]
11. Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time.
Thomson S; Witzke N; Gyawali B; Delos Santos S; Udayakumar S; Cardone C; Cheung MC; Chan KKW
Eur J Cancer; 2021 Jun; 150():203-210. PubMed ID: 33932727
[TBL] [Abstract][Full Text] [Related]
12. Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1.
García-Fumero R; Fernández-López C; Calleja-Hernández MÁ; Expósito-Hernández J
Acta Oncol; 2021 Sep; 60(9):1225-1232. PubMed ID: 34184595
[TBL] [Abstract][Full Text] [Related]
13. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit.
Grössmann N; Del Paggio JC; Wolf S; Sullivan R; Booth CM; Rosian K; Emprechtinger R; Wild C
Eur J Cancer; 2017 Sep; 82():66-71. PubMed ID: 28648700
[TBL] [Abstract][Full Text] [Related]
14. Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'.
Grössmann N; Wolf S; Rothschedl E; Wild C
ESMO Open; 2021 Jun; 6(3):100166. PubMed ID: 34087744
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.
Broekman KE; van Kruchten M; van Tinteren H; Sessa C; Jalving M; Reyners AKL
ESMO Open; 2021 Aug; 6(4):100229. PubMed ID: 34371383
[TBL] [Abstract][Full Text] [Related]
16. Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis.
Cufer T; Ciuleanu TE; Berzinec P; Galffy G; Jakopovic M; Jassem J; Jovanovic D; Mihaylova Z; Ostoros G; Thallinger C; Zemanova M; Zielinski C
Oncologist; 2020 Mar; 25(3):e598-e601. PubMed ID: 32162818
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
Adam R; Tibau A; Molto Valiente C; Šeruga B; Ocaña A; Amir E; Templeton AJ
PLoS One; 2022; 17(6):e0268545. PubMed ID: 35687539
[TBL] [Abstract][Full Text] [Related]
18. The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.
Kiesewetter B; Raderer M; Prager GW; Fuereder T; Marosi C; Preusser M; Krainer M; Locker GJ; Brodowicz T; Zielinski CC
ESMO Open; 2017; 2(3):e000166. PubMed ID: 28761758
[TBL] [Abstract][Full Text] [Related]
19. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
20. Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
Angelis A; Linch M; Montibeller G; Molina-Lopez T; Zawada A; Orzel K; Arickx F; Espin J; Kanavos P
Soc Sci Med; 2020 Feb; 246():112595. PubMed ID: 31874372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]